Centogene announces publication establishing lyso-gb1 as a predictive biomarker for gaucher disease patients

Cambridge, mass. and rostock, germany and berlin, sept. 01, 2023 (globe newswire) -- centogene n.v. (nasdaq: cntg) (the “company”), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced data confirming the utility of lyso-gb1 (glucosylsphingosine) as a sensitive biomarker for gaucher disease (gd). the findings from this landmark study which were published in diagnostics in a paper titled, “insights into the value of lyso-gb1 as a predictive biomarker in treatment-naÏve patients with gaucher disease type 1 in the lyso-proof study,” also indicate lyso-gb1 could help to predict the clinical course of patients and improve personalized care of gd patients in the future.
CNTG Ratings Summary
CNTG Quant Ranking